Plain-English translation of NCT07462650 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new type of cell therapy called dual-target CAR-NK cells, which are immune cells taken from healthy donors and engineered in the laboratory to recognize and attack colorectal cancer cells. The medication is designed to target two or three specific proteins found on cancer cells, which may help it find and destroy tumors more effectively while causing fewer side effects than some other cell therapies. You would receive chemotherapy to prepare your body, followed by an infusion of these engineered cells.
Standard treatments for advanced colorectal cancer don't work for everyone, and some patients become resistant to them over time. This medication offers a potentially new option by using the body's own immune system in a targeted way, with early research suggesting it may be safer than similar therapies and less likely to cause severe side effects.
You likely qualify if…
You likely don't qualify if…
First, the study team will test a sample of your tumor tissue to confirm it has the right markers for the treatment. Then you will receive chemotherapy drugs to prepare your body, followed by hospitalization for close monitoring after you receive an infusion of the engineered immune cells. You may be eligible for a second infusion during the same cycle depending on how you respond. The study involves multiple visits and tests to check how well the treatment is working and to monitor for any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China